Related Articles
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib
Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report
Prognosis and endocrine therapy selection for patients with low hormone receptor‑positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China